{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:32Z","timestamp":1787991392500,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100298","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:40:24Z","timestamp":1783629624000},"page":"100298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa Hunter","family":"Gibble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-544X","authenticated-orcid":false,"given":"Tamara","family":"Al-Zubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-4646","authenticated-orcid":false,"given":"Elizabeth","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Vardavoulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.obpill.2026.100298_bib1","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.obpill.2026.100298_bib2","series-title":"Overweight, obesity and non-communicable diseases [Internet]","year":"2025"},{"key":"10.1016\/j.obpill.2026.100298_bib3","article-title":"Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?","volume":"16","author":"Steenackers","year":"2025","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100298_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamainternmed.2024.6453","article-title":"Lifestyle modification for obesity management\u2014A cornerstone and not a roadblock","volume":"185","author":"Richman","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100298_bib5","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100298_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.obpill.2026.100298_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.obpill.2026.100298_bib8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinthera.2025.05.003","article-title":"Characteristics and treatment patterns of people without type 2 diabetes diagnoses who use tirzepatide in the United States","volume":"47","author":"Gibble","year":"2025","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.obpill.2026.100298_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101636","article-title":"Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States","volume":"51","author":"Hankosky","year":"2025","journal-title":"Diabetes Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2026.100298_bib10","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/dom.16290","article-title":"Real\u2010world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.obpill.2026.100298_bib11","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1111\/dom.16330","article-title":"Real\u2010world use of tirzepatide among individuals without evidence of type 2 diabetes: results from the veradigm\u00ae database. Diabetes","volume":"27","author":"Hunter Gibble","year":"2025","journal-title":"Obes Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100298_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/pop.2024.0239","article-title":"Perspectives on obesity management and the use of anti-obesity medicine from US employees and employers: results from the OBSERVE study","volume":"28","author":"Ard","year":"2025","journal-title":"Popul Health Manag"},{"issue":"1","key":"10.1016\/j.obpill.2026.100298_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JOM.0000000000001144","article-title":"Impact of obesity on work productivity in different US occupations: analysis of the National Health and Wellness Survey 2014 to 2015","volume":"60","author":"Kudel","year":"2018","journal-title":"J Occup Environ Med"},{"issue":"4","key":"10.1016\/j.obpill.2026.100298_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.775","article-title":"Work loss among privately insured employees with overweight and obesity in the United States","volume":"10","author":"Shinde","year":"2024","journal-title":"Obes Sci Pract"},{"issue":"3","key":"10.1016\/j.obpill.2026.100298_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s13679-016-0227-6","article-title":"The impact of obesity in the workplace: a review of contributing factors, consequences and potential solutions","volume":"5","author":"Shrestha","year":"2016","journal-title":"Curr Obes Rep"},{"issue":"1","key":"10.1016\/j.obpill.2026.100298_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41387-024-00352-9","article-title":"Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being","volume":"14","author":"Dall","year":"2024","journal-title":"Nutr Diabetes"},{"issue":"5","key":"10.1016\/j.obpill.2026.100298_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.obpill.2026.100298_bib18","article-title":"The work productivity and activity impairment (WPAI) questionnaire","author":"Walker-Bone","year":"2025","journal-title":"Occup Med (Lond)"},{"key":"10.1016\/j.obpill.2026.100298_bib19","first-page":"1","article-title":"Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: a claims-based analysis","author":"Naber","year":"2025","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"2","key":"10.1016\/j.obpill.2026.100298_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.36469\/jheor.2025.141081","article-title":"Impact of body mass index and comorbidities on health-related quality of life and work productivity in people with overweight or obesity: a survey-based study in the United Kingdom","volume":"12","author":"Leith","year":"2025","journal-title":"Journal of Health Economics and Outcomes Research"},{"key":"10.1016\/j.obpill.2026.100298_bib21","article-title":"Navigating coverage: a qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication","volume":"11","author":"Haggerty","year":"2024","journal-title":"Obes Pillars"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:31:27Z","timestamp":1787988687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"alternative-id":["S2667368126000549"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100298","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100298"}}